Ishihara, Hisamitsu http://orcid.org/0000-0001-8922-6660
Yamaguchi, Susumu
Sugitani, Toshifumi
Kosakai, Yoshinori
Clinical trials referenced in this document:
Documents that mention this clinical trial
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
https://doi.org/10.1007/s40261-019-00851-z
Funding for this research was provided by:
Astellas Pharma
Article History
First Online: 24 September 2019
Compliance with Ethical Standards
:
: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, Good Post-marketing Surveillance Practice, and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Guidelines. Institutional review boards at each site approved the study.
: All patients provided informed consent at Visit 1 before any study-related screening procedures commenced.
: This study was funded by Astellas Pharma Inc.
: HI has served on the scientific advisory board of Astellas Pharma Inc.; received lecture or consulting fees from Astellas Pharma Inc., MSD, Sanofi, Mitsubishi Tanabe Pharma, Boehringer Ingelheim Japan, and Novartis Pharma; and received grants/research support from Astellas Pharma Inc., Ono Pharmaceutical, Boehringer Ingelheim Japan, AstraZeneca, Sanofi, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Daiichi-Sankyo, Novo Nordisk Pharma, Kyowa Hakko Kirin, and MSD. SY, TS, and YK are employees of the study sponsor.